How many units of tesamorelin do I draw?

It depends on the water volume, which sets the concentration. Enter the vial size and water volume in the calculator for the unit mark. The reconstitution chart below tabulates the common combinations.

Why is the dose the same at every experience level?

Because the engine dose table carries one figure for it across the levels, which is what you would expect from a compound with a licensed daily dose rather than a community-titrated range. The table on this page shows it explicitly rather than inventing a ramp to fill the columns.

Why do I see a lower maximum quoted elsewhere?

Because the two Klarovel sources differ, and the page shows both. The engine dose table holds the licensed daily figure; the research row holds a lower conservative wellness figure. The engine dose table is the one that binds in production, because the dose guard reads its ceilings from there and falls back to the research row only where no dose row exists.

Does tesamorelin have to be taken fasted?

The engine catalog carries a bedtime timing and a fasting interval for it, both shown in the administration section on this page, taken verbatim from the catalog rather than paraphrased.

Does body weight change the dose?

No. The engine catalog does not flag tesamorelin weight sensitive and the dose calculator applies no generic weight scaling. A licensed fixed daily dose is exactly the case where inventing a per-kilogram rule would be wrong.

Does tesamorelin need cycling?

The engine catalog carries an on-period, an off-period, a micro-cycle pattern and a taper flag for it. All of these are shown on this page and the on-period drives the supplies plan.

When is tesamorelin not appropriate?

The conditions table on this page is the longest of this set: the engine's contraindication matrix associates several conditions with this compound and its category, including ones that block, ones that caution, ones that trigger monitoring and one that reduces the dose. Each row carries the engine's own stated reason.

Where do the numbers on this page come from?

The dose table, the ceilings and the frequency come from the Klarovel engine's own dose table, the same rows the protocol generator doses from. Route, timing, cycling and weight sensitivity come from the engine catalog. Nothing on this page is a number someone typed into an article, which is the failure mode most dosing pages share.

Is this calculator free?

Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.

Does Klarovel sell this peptide?

No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel.

Is this medical advice?

No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

Tesamorelin dosage calculator

Tesamorelin is the one compound on this set of pages with a licensed human dose behind it, which makes the arithmetic straightforward and the ceiling question interesting.

Below the calculator: a reconstitution chart, the dose envelope per experience level, the cycle length, a supplies plan, the health conditions that change the answer, and the references. Every dose figure is read from the Klarovel engine's dose table, never typed into the page.

How many milligrams are in your Tesamorelin vial?

How much bacteriostatic water are you adding?

Syringe size

Experience with injectable peptides

Selects the dose row the engine would use, which changes the target, the upper bound and the ceiling together.

Body weight

The engine catalog does not flag Tesamorelin weight sensitive, and the dose calculator applies no generic weight scaling, so this does not change the target. Inventing a per-kilogram rule would be worse than leaving it alone.

Age 65 or over

Standard dose at the beginner level

40.0 units

2 mg

Concentration: 5 mg/ml
Injection volume: 0.4 ml
Doses per vial: 5

Frequency for this level: once daily. Timing: Bedtime. Route: subcutaneous.

Phase by phase, at your mix

The three phases in the order the engine escalates a dose, with the unit mark for each at 10 mg in 2 ml. Change the experience level, weight or age above and the whole table recomputes.

Dose and syringe units per titration phase
Phase	Dose	Draw	Doses per vial
Phase 1, opening dose	2 mg	40.0 units	5
Phase 2, standard dose	2 mg	40.0 units	5
Phase 3, upper dose	2 mg	40.0 units	5
Ceiling, not exceeded	2 mg	40.0 units	5

Doses read from the beginner row of dose_protocols, the engine's dose table. Unit marks are arithmetic over your vial size and water volume.

Tesamorelin dose envelope by experience level

Every level side by side, unmodified. This is the raw dose table, so the shape of the ramp is visible instead of collapsed into a single recommended number.

Dose envelope per experience level
Experience	Opening	Standard	Upper	Ceiling	Frequency
Never used peptides	2 mg	2 mg	2 mg	2 mg	once daily
Researched, not used	2 mg	2 mg	2 mg	2 mg	once daily
Beginner	2 mg	2 mg	2 mg	2 mg	once daily
Intermediate	2 mg	2 mg	2 mg	2 mg	once daily
Experienced	2 mg	2 mg	2 mg	2 mg	once daily

Every cell read verbatim from dose_protocols. Where a level repeats the same figure across columns, that is what the table holds: no ramp has been invented to fill the row.

Tesamorelin reconstitution chart

Pre-calculated syringe units for every water volume against the dose figures this compound actually uses, at your selected vial size of 10 mg. A cell reading "n/a" means the draw exceeds a 100-unit syringe at that concentration.

Syringe units per water volume for each sourced dose figure
BAC water	Conc.	Opening2 mg	Standard2 mg	Upper2 mg	Ceiling2 mg
1 ml	10 mg/ml	20	20	20	20
1.5 ml	6.67 mg/ml	30	30	30	30
2 ml	5 mg/ml	40	40	40	40
2.5 ml	4 mg/ml	50	50	50	50
3 ml	3.33 mg/ml	60	60	60	60
4 ml	2.5 mg/ml	80	80	80	80
5 ml	2 mg/ml	100	100	100	100

Column doses are the beginner row's opening, standard, upper and ceiling figures from dose_protocols. Unit marks are arithmetic.

Supplies for one cycle

One on-cycle runs 12 weeks followed by 4 weeks off, from the engine catalog. Multiplied out at the standard dose and your mix, that is what the cycle costs in consumables.

Bacteriostatic water bottle size

Supplies for one on-cycle
Cycle length	12 weeks on, 4 weeks off
Administrations per week	7
Total administrations	84
Vials of 10 mg	17
Insulin syringes	84 (50-unit holds the draw)
Bacteriostatic water	34 ml, 4 bottles of 10 ml

Cycle length, loading phase and taper from PEPTIDE_CATALOG. Administrations per week derived from the frequency string on the dose row. Counts are arithmetic.

Save your reconstitution. Get the protocol it belongs in.

Free founding-member access while spots last. We'll send your reconstitution + a link to claim your slot.

About Tesamorelin

Tesamorelin is a growth hormone releasing hormone analogue. It has been through randomised controlled trials for visceral fat reduction, with published population pharmacokinetics, long-term safety follow-up and later work on hepatic fat and neurocognitive endpoints. Its evidence base is the deepest in this group.

It is dosed daily at bedtime on an empty stomach, and the catalog carries a fasting interval for it. That is a real constraint on the schedule rather than a preference.

Two Klarovel data sources carry different upper bounds for it: the engine dose table holds the licensed daily dose, while the research row holds a lower conservative figure. The page shows both and names which one binds. Hiding the disagreement would be the easier choice and the wrong one.

Administration and cycling

Administration and cycling reference
Route	subcutaneous
Timing	Bedtime
Catalog frequency	once daily
Cycle	12 weeks on, 4 weeks off
Taper before the off period	Yes
Loading phase	None
Weight sensitive	No

Catalog note: Inject subcutaneously at bedtime on an empty stomach (at least 2 hours after last meal). FDA-approved for visceral fat reduction.

Every row above is read from PEPTIDE_CATALOG, the engine catalog, and the note is quoted verbatim rather than paraphrased.

Two ceilings, and which one binds

Klarovel holds two upper bounds for Tesamorelin in two different places, and they do not agree. The engine dose table puts the highest ceiling at 2 mg across the experience levels. The older research row carries 1 mg.

The engine dose table is the one that binds. The dose guard that caps generated protocols reads its ceilings from that table and falls back to the research row only where no dose row exists, because a guard that fights the engine trims legitimately curated doses and trains everyone to ignore its warnings.

Both figures are printed here rather than one, so a reader who finds the lower number elsewhere can see that both exist and which one the software actually uses.

When this would not be recommended for you

A public page cannot know your health data, so it cannot tell you whether a compound is appropriate. What it can do is list the conditions the engine's contraindication matrix associates with this compound, and what the engine does about each. In a generated protocol these resolve automatically and the reason is shown alongside the exclusion.

Health conditions and the engine's action
Condition	Engine action	Reason
Cancer history	Caution	GH-releasing peptides may increase IGF-1, which is involved in cell growth. Requires oncological clearance before use with cancer history.
Diabetes type1	Caution	GH-releasing peptides may increase blood sugar via GH-induced insulin resistance. Requires close blood sugar monitoring with type 1 diabetes.
Heart condition	Caution	GH-releasing peptides may affect fluid balance and cardiac load. Requires cardiological clearance with heart disease.
Diabetes type2	Monitored	GH-releasing peptides may moderately affect blood sugar. Monitor fasting glucose and HbA1c with type 2 diabetes.
Thyroid	Monitored	GH-releasing peptides may affect thyroid function. Monitor TSH, free T3, and free T4 with thyroid disease.
Kidney	Dose reduced (75%)	Reduced kidney function may affect peptide clearance. Dose reduction recommended with kidney disease.

Conditions, severities and reasons read verbatim from CONTRAINDICATION_RULES, the engine's contraindication matrix. This is not the full set of things worth raising with a clinician; it is the set the engine acts on.

Questions

How many units of tesamorelin do I draw?: It depends on the water volume, which sets the concentration. Enter the vial size and water volume in the calculator for the unit mark. The reconstitution chart below tabulates the common combinations.
Why is the dose the same at every experience level?: Because the engine dose table carries one figure for it across the levels, which is what you would expect from a compound with a licensed daily dose rather than a community-titrated range. The table on this page shows it explicitly rather than inventing a ramp to fill the columns.
Why do I see a lower maximum quoted elsewhere?: Because the two Klarovel sources differ, and the page shows both. The engine dose table holds the licensed daily figure; the research row holds a lower conservative wellness figure. The engine dose table is the one that binds in production, because the dose guard reads its ceilings from there and falls back to the research row only where no dose row exists.
Does tesamorelin have to be taken fasted?: The engine catalog carries a bedtime timing and a fasting interval for it, both shown in the administration section on this page, taken verbatim from the catalog rather than paraphrased.
Does body weight change the dose?: No. The engine catalog does not flag tesamorelin weight sensitive and the dose calculator applies no generic weight scaling. A licensed fixed daily dose is exactly the case where inventing a per-kilogram rule would be wrong.
Does tesamorelin need cycling?: The engine catalog carries an on-period, an off-period, a micro-cycle pattern and a taper flag for it. All of these are shown on this page and the on-period drives the supplies plan.
When is tesamorelin not appropriate?: The conditions table on this page is the longest of this set: the engine's contraindication matrix associates several conditions with this compound and its category, including ones that block, ones that caution, ones that trigger monitoring and one that reduces the dose. Each row carries the engine's own stated reason.
Where do the numbers on this page come from?: The dose table, the ceilings and the frequency come from the Klarovel engine's own dose table, the same rows the protocol generator doses from. Route, timing, cycling and weight sensitivity come from the engine catalog. Nothing on this page is a number someone typed into an article, which is the failure mode most dosing pages share.
Is this calculator free?: Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.
Does Klarovel sell this peptide?: No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel.
Is this medical advice?: No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

Other peptide calculators

References

These papers cover the tesamorelin randomised trials, its population pharmacokinetics, long-term safety follow-up, and the visceral fat, hepatic fat and metabolic endpoints studied.

The dose figures on this page are not sourced from these papers. They are read from the Klarovel engine's own dose table, which is cited inline wherever a number appears. These references cover mechanism, pharmacology and clinical context.

18 references, every identifier resolved against NCBI on 2026-07-30. Per peptide, a relevance-sorted esearch was run and every returned id was resolved through esummary. Any id esummary could not resolve was dropped, and any record carrying the 'Retracted Publication' pubtype was dropped. Titles, journals, years and first authors below are the values esummary returned, not authored text. One retracted record was dropped: PMID 37696839 (thymosin beta 4 query).

1.Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA 2014. PMID 25038357 PMC4363137
2.Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 2010. PMID 20554713
3.Falutz J et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr 2010. PMID 20101189
4.Falutz J et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008. PMID 18690162
5.Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 2019. PMID 31611038 PMC6981288
6.Dhillon S et al. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs 2011. PMID 21668043
7.Spooner LM et al. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother 2012. PMID 22298602
8.González-Sales M et al. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet 2015. PMID 25358450
9.González-Sales M et al. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. J Pharmacokinet Pharmacodyn 2015. PMID 25895899
10.Stanley TL et al. Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction. AIDS 2011. PMID 21516030 PMC3673013
11.Fourman LT et al. Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV. AIDS 2017. PMID 28832410 PMC5633509
12.Lake JE et al. Tesamorelin improves fat quality independent of changes in fat quantity. AIDS 2021. PMID 33756511 PMC8243807
13.Mangili A et al. Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PLoS One 2015. PMID 26457580 PMC4601733
14.Stanley TL et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis 2012. PMID 22495074 PMC3348954
15.Ellis RJ et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. J Infect Dis 2025. PMID 39813152
16.Russo SC et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS 2024. PMID 38905488 PMC11365754
17.Adrian S et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging 2019. PMID 31237318 PMC6766405
18.Tomlinson B et al. Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor. Curr Opin Investig Drugs 2006. PMID 17086939

Beyond the arithmetic

Your health data, your protocol.

A calculator converts a dose into syringe units. The Klarovel engine decides the dose: it reads your health data, resolves contraindications, sets the envelope by experience level, removes incompatible pairs and builds the cycling and monitoring schedule. Blood work is optional and sharpens the result. It is never required.